Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus REDEMPLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus REDEMPLO.
IMPOYZ vs REDEMPLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
REDEMPLO is a synthetic tricyclic analog that acts as a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It binds to the presynaptic transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT), inhibiting their reuptake and increasing synaptic concentrations of these monoamines. Additionally, it has weak antagonistic properties at the 5-HT2A and alpha-2 adrenergic receptors, contributing to its antidepressant and anxiolytic effects.
100 mg orally twice daily
100 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and end-stage renal disease (up to 40 hours).
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily hepatic metabolism with 70% renal excretion of metabolites and 30% fecal elimination; less than 5% excreted unchanged in urine.
Category C
Category C
Unknown
Unknown